THE APEX TIMES
A Yahoo Finance report posted on Stocktwits says BlackRock and Vanguard Capital Management bought five stocks in the third quarter, including new positions in SLS, IBRX and IOVA.
BlackRock’s third-quarter buying activity, as summarized in a Yahoo Finance report that circulated via Stocktwits, points to a broad sweep into both health care and biotech names. The post says BlackRock and its affiliated asset-management unit, Vanguard Capital Management, added all five stocks on its Q3 buy list.
Three of the newly added positions highlighted in the report were Sarepta Therapeutics (SLS), IRhythm Technologies (IBRX), and Innoviva (IOVA). The post attributes 8.12 million shares across those three stocks to the Q3 additions, though it does not break out how many shares were attributed to each company.
The same report also links the Q3 buy list to established pharmaceuticals, stating that Merck (MRK) and Eli Lilly (LLY) were among the five names added. It frames the action as part of BlackRock’s and Vanguard Capital Management’s broader rebalancing or investment updates for the quarter.
The post further claims that a Vanguard unit “adds all of them too,” indicating that the purchasing activity was not limited to BlackRock’s direct footprint. However, the post does not identify which specific Vanguard entity or vehicle performed the additional buying, nor does it specify whether the shares reflect new positions or increased stakes.
In corporate filings and portfolio disclosures, such Q3 lists are often associated with quarterly reporting of holdings by large managers and their affiliated investment platforms. BlackRock and Vanguard entities manage large index and active strategies, and changes to holdings can be driven by client flows, index methodology, or manager rebalancing decisions. In this case, the report provides the headline names and share totals but does not provide the underlying filing details, portfolio weight changes, or the time window of the transactions.
Sector context matters for how investors read these kinds of lists. The mix described in the report includes health care and life sciences exposure, which can range from late-stage drug developers to medtech and specialty pharma. Shifts into these areas can also reflect broader rotation into segments seen as having differentiated pipelines, recurring demand, or product cycles, although the post does not cite any company fundamentals behind the buying.
What remains unclear from the Stocktwits repost is the depth of the activity. The post does not provide cost basis, average purchase prices, percentage ownership after the trades, or whether SLS, IBRX, and IOVA were brand-new positions versus adds to existing exposure. It also does not say whether the report reflects consolidated holdings, model portfolios, or specific fund mandates.
Investors watching next may want to compare the report’s share figures to the managers’ formal quarterly disclosures and to any subsequent reporting that clarifies whether the holdings represent new starts or follow-on purchases. If additional documentation is published, it could also shed light on how large the stakes are relative to the managers’ portfolios and whether the buying aligns with particular strategies or client mandates.
A new market note argues Coinbase still looks like a difficult bet, pointing to how far the stock has fallen from its recent high as crypto sentiment remains fragile.
A recent Yahoo Finance piece revisits the long-running skepticism from Berkshire Hathaway’s chairman and weighs whether bitcoin has proved him right, underscoring how quickly “old guard” views can become headline catalysts.
A new comparison of Coinbase Global and Mastercard highlights how the stocks are being judged on different fundamentals, with Coinbase facing a revenue decline while Mastercard’s profitability stands out, and the market pricing the two narratives at very different multiples.
The update pegs a revised valuation roughly 22% above the stock’s level at the time of the post, with the author pointing to a dominant contributor to the estimate.
President Trump said he would cap credit card interest rates at 10%, a step that would run counter to a reported industry median card rate near 22.2%. The proposal could pressure earnings models for major lenders such as JPMorgan Chase and Citigroup, depending on how the cap is designed and enforced.
Tracking 13F reports for the quarter ended Sept. 30, 20 large funds reported buying Mastercard while 18 reported selling, a split that highlights how institutional positioning can diverge even when the same stock is in the spotlight.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...